Form 4: Eli Lilly director adds shares via deferral plan

Director J. Erik Fyrwald reported acquisitions of Eli Lilly stock and deferred stock units on Nov. 17, 2025, lifting direct beneficial ownership to 74,988.689 shares.

Summary

• On 11/17/2025, Director J. Erik Fyrwald reported two acquisitions of Eli Lilly common stock coded “A”: 9.706 shares (deferred as stock units) and 215.327 shares, both at $1,021.7 per share.
• Following the second transaction, direct beneficial ownership stands at 74,988.689 shares.
• The 9.706 shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after separation from service.
• Form 4 was signed by Jonathan Groff for J. Erik Fyrwald on 11/18/2025.
• Reporting person’s relationship to issuer: Director.

Sentiment

Score: 6

Explanation: Net insider accumulation with no sales; however, the activity reflects routine board compensation/deferral rather than open‑market buying, so the signal is modestly positive.

Positives

• Insider increased holdings with no sales disclosed.
• Direct beneficial ownership now totals 74,988.689 shares after the reported transactions.
• Use of the Directors' Deferral Plan indicates long-term alignment of director compensation with shareholder interests.

Negatives

• Acquisitions were awards/deferrals (Code “A”) rather than open‑market purchases, offering a weaker confidence signal.
• Incremental additions are modest relative to existing holdings.

Future Outlook

Deferred stock units will be settled in shares of common stock following the director’s separation from service; no additional outlook or guidance is provided.

Management Comments

• At the election of the reporting person, the acquired shares in the first transaction were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares following separation from service.

Industry Context

Director equity awards and deferral programs are standard among large-cap pharmaceutical companies and are generally viewed as governance-aligned but only modestly informative about near-term business performance.

Comparison to Industry Standards

• Comparable to practices at Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ), whose directors may defer retainers into stock units that settle upon departure; this transaction aligns with that governance norm.
• The use of stock units rather than cash is typical for large-cap boards seeking to align director incentives with long-term shareholder value.
• No open‑market purchases were disclosed, consistent with many peer director transactions that are primarily equity grants or deferrals rather than discretionary buying.

Related Party Transactions

• Director elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in Eli Lilly common shares after separation.
• Acquisition of 215.327 shares coded as “A” (award/other acquisition) from the issuer.

Stakeholder Impact

• Aligns director incentives more closely with shareholders through increased equity exposure.
• No operational impact and minimal dilution beyond ordinary-course director equity awards.

Next Steps

• Deferred stock units to be settled in shares following the director’s separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, insider transaction, director stock, Directors' Deferral Plan, stock units, beneficial ownership, insider buying, equity award